Ask AI
ProCE Banner Activity

Cholinergic Connection: Beyond Dopamine Blockade in Schizophrenia Care

Clinical Thought

Read this commentary exploring how muscarinic receptor modulation is reshaping our understanding of schizophrenia treatment. Moving beyond direct dopamine receptor inhibition, we can now engage upstream circuits and offer patients more targeted, tolerable, and functionally meaningful care.

Released: December 18, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with Practicing Clinicians Exchange (PCE)

ProCE Banner

Supporters

Supported by an educational grant from Bristol-Myers Squibb.

Bristol Myers Squibb

Partners

Practicing Clinicians Exchange, LLC

ProCE Banner

Target Audience

This activity is intended for healthcare professionals caring for patients with schizophrenia including psychiatrists, physicians, nurse practitioners, physician associates, registered nurses, pharmacists, social workers, and psychologists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the characteristics of novel and emerging therapeutic agents for schizophrenia beyond antidopaminergic antipsychotics, including mechanisms of action and pharmacokinetics

  • Differentiate evidence for efficacy and safety profiles of novel agents used in the treatment of schizophrenia

  • Explain the potential of novel antipsychotics in transforming clinical practice by addressing unmet needs of current schizophrenia treatments

Disclosure

Primary Author

Michael Asbach, DMSc, PA-C: consultant/advisor/speaker: AbbVie, Axsome Therapeutics, Bristol Myers Squibb, Johnson & Johnson, Intra-Cellular, Neurocrine Biosciences, Otsuka, Sage/Biogen, Teva.